SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 3, 2006, Pages 1013-1020

  Malcolm, B A ^a   Liu, R ^a   Lahser, F ^a   Agrawal, S ^a   Belanger, B ^a   Butkiewicz, N ^a   Chase, R ^a   Gheyas, F ^a   Hart, A ^a   Hesk, D ^a   Ingravallo, P ^a   Jiang, C ^a   Kong, R ^a   Lu, J ^a   Pichardo, J ^a   Prongay, A ^a   Skelton, A ^a   Tong, X ^a   Venkatraman, S ^a   Xia, E ^a   Girijavallabhan, V ^a   Njoroge, F G ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; NONSTRUCTURAL PROTEIN 3; POLYPROTEIN; PROTEINASE INHIBITOR; SCH 503034; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CELL MATURATION; DRUG EFFICACY; DRUG MECHANISM; ENDOPLASMIC RETICULUM; HEPATITIS C; HEPATITIS C VIRUS; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CLONE CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HEPACIVIRUS; HEPATOCYTES; HUMANS; HYDROLYSIS; INTERFERON-ALPHA; LIVER NEOPLASMS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEASE INHIBITORS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; REPLICON; VIRAL NONSTRUCTURAL PROTEINS;

EID: 33644639990     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.3.1013-1020.2006     Document Type: Article

References (48)

1. Alter, H. J., and L. B. Seeff. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20:17-35.
2. Bain, V. G. 2001. Effect of HCV viral dynamics on treatment design: lessons learned from HIV. Am. J. Gastroenterol. 96:2818-2828.
3. Bartenschlager, R., L. Ahlborn-Laake, J. Mous, and H. Jacobsen. 1993. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type pro-teinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 67:3835-3844.
4. Bazan, J. F., and R. J. Fletterick. 1988. Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications. Proc. Natl. Acad. Sci. USA 85:7872-7876.
5. Berger, A., and I. Schechter. 1970. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 257:249-264.
6. Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
7. Choo, Q.-L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-364.
8. De Francesco, R. P., and C. Steinkuhler. 1998. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase. Antivir. Ther. 3:99-109.
9. D'Souza, E. D., E. O'Sullivan, E. M. Amphlett, D. J. Rowlands, D. V. Sangar, and B. E. Clarke. 1994. Analysis of NS3-mediated processing of the hepatitis C virus non-structural region in vitro. J. Gen. Virol. 75:3469-3476.
10. Failla, C. M., E. Pizzi, R. De Francesco, and A. Tramontano. 1996. Redesigning the substrate specificity of the hepatitis C virus NS3 protease. Struct. Folding Design 1:35-42.
11. Foy, E., K. Li, R. Sumpter, Jr., Y.-M. Loo, C. L. Johnson, C. Wang, P. M. Fish, M. Yoneyama, T. Fujita, S. M. Lemon, and M. Gale, Jr. 2005. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-1 signaling. Proc. Natl. Acad. Sci. USA 102:2986-2991.
12. Foy, E., K. Li, C. Wang, R. Sumpter, Jr., M. Ikeda, S. M. Lemon, and M. Gale, Jr. 2003. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300:1145-1148.
13. Gorbalenya, A. E., E. V. Koonin, A. P. Donchenko, and V. M. Blinov. 1989. Coronavirus genome: prediction of putative functional domains in the non-structural polyprotein by comparative amino acid sequence analysis. Nucleic Acids Res. 17:4847-4861.
14. Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 67:2832-2843.
15. Hijikata, M., H. Mizushima, T. Akagi, S. Mori, N. Kakiuchi, N. Kato, T. Tanaka, K. Kimura, and K. Shimotohno. 1993. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J. Virol. 67:4665-4675.
16. Hu, K. Q., J. M. Vierling, and A. G. Redeker. 2001. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J. Viral Hepat. 8:1-18.
17. Kim, J. L., K. A. Morgenstern, C. Lin, T. Fox, M. D. Dwyer, J. A. Landro, S. P. Chambers, W. Markland, C. A. Lepre, E. T. O'Malley, S. L. Harbeson, C. M. Rice, M. A. Murcko, P. R. Caron, and J. A. Thomson. 1996. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343-355. (Erratum, 89:159.)
18. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bos, D. R. Cameron, M. Cartier, M. G. Cordingley, A.-M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagace, S. R. LaPlante, H. Narjes, M.-A. Poupart, J. Rancourt, R. E. Sentjens, R. St. George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C.-L. Yong, and M. Llinas-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
19. Lewis, S. D., B. J. Lucas, S. F. Brady, J. T. Sisko, K. J. Cutrona, P. E. J. Sanderson, R. M. Freidinger, S.-S. Mao, S. J. Gardell, and J. A. Shafer. 1998. Characterization of the two-step pathway for inhibition of thrombin by alpha-ketoamide transition state analogs. J. Biol. Chem. 273:4843-4854.
20. Lin, C., B. M. Pragai, A. Grakoui, J. Xu, and C. M. Rice. 1994. Hepatitis C virus NS3 serine proteinase: trans-cleavage requirements and processing kinetics. J. Virol. 68:8147-8157.
21. Lin, C., J. A. Thomson, and C. M. Rice. 1995. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J. Virol. 69:4373-4380.
22. Lin, K., A. D. Kwong, and C. Lin. 2004. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob. Agents Chemother. 48:4784-4792.
23. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
24. Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
25. Love, R. A., H. E. Parge, J. A. Wickersham, Z. Hostomsky, N. Habuka, E. W. Moomaw, T. Adachi, and Z. Hostomska. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331-342.
26. Malich, G., B. Markovic, and C. Winder. 1997. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 124:179-192.
27. Manabe, S., I. Fuke, O. Tanishita, C. Kaji, Y. Gomi, S. Yoshida, C. Mori, A. Takamizawa, I. Yosida, and H. Okayama. 1994. Production of nonstructural proteins of hepatitis C virus requires a putative viral protease encoded by NS3. Virology 198:636-644.
28. Manns, M. P., J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
29. Mercer, D. F., D. E. Schiller, J. F. Elliott, D. N. Douglas, C. Hao, A. Rinfret, W. R. Addison, K. P. Fischer, T. A. Churchill, J. R. Lakey, D. L. Tyrrell, and N. M. Kneteman. 2001. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7:927-933.
30. Morrison, J. F., and C. T. Walsh. 1988. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61: 201-301.
31. Neumann, A. U., N. P. Lam, H. Dahari, D. R. Gretch, T. E. Wiley, T. J. Layden, and A. S. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
32. O'Connell, M. A., and R. D. Wolfinger. 1997. Spatial regression models, response surfaces, and process optimization. J. Comput. Graph. Stat. 6:224-241.
33. Perni, R. B., J. Pitlik, S. D. Britt, J. J. Court, L. F. Courtney, D. D. Deininger, L. J. Farmer, C. A. Gates, S. L. Harbeson, and R. B. Levin. 2004. Inhibitors of hepatitis C virus NS3 · 4A protease 2. Warhead SAR and optimization. Bioorg. Med. Chem. Lett. 14:1441-1446.
34. Pietschmann, T., V. Lohmann, G. Rutter, K. Kurpanek, and R. Bartenschlager. 2001. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:1252-1264.
35. Reed, K. E., and C. M. Rice. 2000. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Topics Microbiol. Immunol. 242:55-84.
36. Resnick, H. W., S. Zeuzem, A. van Vliet, L. McNair, S. Purdy, H-M. Chu, and P. L. Jansen. 2005. Initial results of a phase Ib, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor, abstr. 527. Digestive Disease Week, 14 to 19 May 2005, Chicago, Ill.
37. St. Charles, R., J. H. Matthews, E. Zhang, and A. Tulinsky. 1999. Bound structures of novel P3-p1′ beta-strand mimetic inhibitors of thrombin. J. Med. Chem. 42:1376-1383.
38. Taremi, S., B. M. Beyer, M. Maher, N. Yao, W. Prosise, P. C. Weber, and B. A. Malcolm. 1998. Construction, expression, and characterization of a novel fully activated recombinant single-chain hepatitis C virus protease. Protein Sci. 7:2143-2149.
39. Tomei, L., C. Failla, E. Santolini, R. De Francesco, and N. La Monica. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J. Virol. 67:4017-4026.
40. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
41. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20:1-16.
42. Wolk, B., D. Sansonno, H. G. Krausslich, F. Dammacco, C. M. Rice, H. E. Blum, and D. Moradpour. 2000. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J. Virol. 74:2293-2304.
43. Yao, N., P. Reichert, S. S. Taremi, W. W. Prosise, and P. C. Weber. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Struct. Folding Design 7:1353-1363.
44. Yip, Y., F. Victor, J. Lamar, R. Johnson, Q. M. Wang, D. Barket, J. Glass, L. Jin, L. Liu, and D. Venable. 2004. Discovery of a novel bicycloproline P2 bearing peptidyl α-ketoamide LY514962 as HCV protease inhibitor. Bioorg. Med. Chem. Lett. 14:251-256.
45. Zhang, R., B. M. Beyer, J. Durkin, R. Ingram, F. G. Njoroge, W. T. Windsor, and B. A. Malcolm. 1999. A continuous spectrophotometric assay for the hepatitis C virus serine protease. Anal. Biochem. 270:268-275.
46. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:9294-9299.
47. Zhong, J., and W. C. Groutas. 2004. Recent developments in the design of mechanism-based and alternate substrate inhibitors of serine proteases. Curr. Top. Med. Chem. 4:1203-1216.
48. Zylberberg, H., M. L. Chaix, and C. Brechet. 2000. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann. Intern. Med. 132:845-846.